Long Noncoding RNA PVT1 as a Novel Diagnostic Biomarker and Therapeutic Target for Melanoma

Figure 2

Serum PVT1 expression levels in melanoma patients and its diagnostic values for melanoma. (a) Serum PVT1 expression levels in 51 melanoma patients and 47 nonmelanoma controls with melanocytic nevus were measured by qPCR. by Mann–Whitney test. (b) Serum PVT1 expression levels in 51 melanoma patients with different clinical stages were measured by qPCR. by Mann–Whitney test. (c) ROC curve analysis of serum PVT1 levels for discrimination between melanoma patients and nonmelanoma controls with melanocytic nevus (AUC: 0.9387 (95% CI: 0.8899–0.9874), sensitivity: 94.12%, specificity: 85.11%). (d) ROC curve analysis of serum PVT1 levels for discrimination between stage I melanoma patients and nonmelanoma controls with melanocytic nevus (AUC: 0.8684 (95% CI: 0.7611–0.9756), sensitivity: 87.50%, and specificity: 85.11%).

(a)

(b)

(c)

(d)